Stock SVRA SAVARA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Savara Inc. Stock

Equities

SVRA

US8051111016

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 11:55:47 2024-04-19 am EDT 		5-day change 1st Jan Change
4.755 USD -0.73% Intraday chart for Savara Inc. -6.31% +1.06%
Apr. 12 Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection CI
Apr. 08 Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024 CI

Financials (USD)

Sales 2024 * - Sales 2025 * 10.07M Capitalization 662M
Net income 2024 * -68M Net income 2025 * -58M EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 65.7 x
P/E ratio 2024 *
-12.3 x
P/E ratio 2025 *
-12.4 x
Employees 37
Yield 2024 *
-
Yield 2025 *
-
Free-Float 93.83%
More Fundamentals * Assessed data

Chart Savara Inc.

Dynamic Chart

Latest news about Savara Inc.

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection CI
Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024 CI
Transcript : Savara Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM
Savara Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Savara Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating MT
JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target MT
Savara Insider Sold Shares Worth $395,900, According to a Recent SEC Filing MT
Savara Insider Sold Shares Worth $442,291, According to a Recent SEC Filing MT
Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis CI
Savara Inc.(NasdaqGS:SVRA) added to NASDAQ Biotechnology Index CI
Savara Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Guggenheim Starts Savara With Buy Rating, $7 Price Target MT
Savara Inc.(NasdaqGS:SVRA) added to S&P Global BMI Index CI
HC Wainwright Adjusts Price Target on Savara to $6 From $3, Keeps Buy Rating MT
More news

Latest transcript on Savara Inc.

Logo Savara Inc.
Savara Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 08:00 AM
More transcripts

Analyst Recommendations on Savara Inc.

Piper Sandler Adjusts Price Target on Savara to $16 From $7, Maintains Overweight Rating MT
JMP Securities Starts Savara With Market Outperform Rating, $8 Price Target MT
Guggenheim Starts Savara With Buy Rating, $7 Price Target MT
HC Wainwright Adjusts Price Target on Savara to $6 From $3, Keeps Buy Rating MT
Jefferies Downgrades Savara to Hold From Buy With $2 Price Target MT
More recommendations

Press releases Savara Inc.

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024 BU
Savara Announces New Employment Inducement Grant AQ
Savara Announces New Employment Inducement Grant BU
Savara Reports Fourth Quarter/Year-End 2023 Financial Results and Provides Business Update BU
Savara to Present at the Barclays 26th Annual Global Healthcare Conference BU
More press releases

News in other languages on Savara Inc.

Relief Therapeutics se dote d'un responsable des opérations
Relief Therapeutics ernennt Taneli Jouhikainen zum Chief Operating Officer
More news

Quotes and Performance

1 day-3.43%
1 week-10.30%
Current month-3.82%
1 month+1.70%
3 months+12.18%
6 months+43.41%
Current year+1.91%
More quotes

Highs and lows

1 week
4.79
Extreme 4.79
5.30
1 month
4.52
Extreme 4.5201
5.34
Current year
4.12
Extreme 4.115
5.70
1 year
1.76
Extreme 1.76
5.70
3 years
1.02
Extreme 1.02
5.70
5 years
0.69
Extreme 0.69
11.96
10 years
0.69
Extreme 0.69
17.19
More quotes

Managers and Directors - Savara Inc.

Managers TitleAgeSince
Matthew Pauls CEO
 Chief Executive Officer 53 17-04-26
David Lowrance DFI
 Director of Finance/CFO 56 17-04-26
Robert M. Lutz COO
 Chief Operating Officer 55 23-02-12
Members of the board TitleAgeSince
David Ramsay BRD
 Director/Board Member 59 17-04-26
Richard Hawkins BRD
 Director/Board Member 75 10-09-30
Nevan Elam BRD
 Director/Board Member 56 09-01-31
More insiders

ETFs positioned on Savara Inc.

Name Weight AuM 1st Jan change Investor Rating
UNLIMITED HFND MULTI-STRATEGY RETURN TRACKER ETF - USD ETF Unlimited HFND Multi-Strategy Return Tracker ETF - USD
0.00% 34 M€ +1.04% -
More ETFs positioned on Savara Inc.

Quotes

Date Price Change Volume
24-04-19 4.75 -0.84% 199 270
24-04-18 4.79 -3.43% 1,204,829
24-04-17 4.96 -3.88% 2,063,515
24-04-16 5.16 +2.38% 2,143,934
24-04-15 5.04 -0.59% 1,857,117

Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT

More quotes

Company Profile

Savara Inc. is a clinical-stage biopharmaceutical company, which is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. Molgramostim nebulizer solution is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the molgramostim aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Sector
Biotechnology & Medical Research
Calendar
2024-05-08 - Q1 2024 Earnings Release (Projected)
Related indices
Russell 2000
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.79 USD
Average target price
8.786 USD
Spread / Average Target
+83.42%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SAVARA INC. Stock Savara Inc.
+1.91% 662M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.30% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.79% 96.07B
ARGENX SE Stock argenx SE
-1.43% 21.66B
BIONTECH SE Stock BioNTech SE
-18.35% 20.77B
GENMAB A/S Stock Genmab A/S
-8.65% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-40.31% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-26.84% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.59% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+20.86% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. SVRA Stock